published meta-analysis   sensitivity analysis   studies

control in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsITAC, 2022 0.80 [0.42; 1.52] 0.80[0.42; 1.52]ITAC, 202210%579NAnot evaluable deathsdetailed resultsACTIV-3/TICO LY-CoV555 , 2020 1.71 [0.56; 5.21] ITAC, 2022 0.80 [0.42; 1.52] 1.01[0.51; 2.01]ACTIV-3/TICO LY-CoV555 , 2020, ITAC, 2022225%893moderatenot evaluable clinical improvementdetailed resultsACTIV-3/TICO LY-CoV555 , 2020 0.85 [0.56; 1.29] ITAC, 2022 1.06 [0.77; 1.45] 0.98[0.76; 1.26]ACTIV-3/TICO LY-CoV555 , 2020, ITAC, 202220%899moderatenot evaluable clinical improvement (7-day)detailed resultsACTIV-3/TICO LY-CoV555 , 2020 0.85 [0.56; 1.29] ITAC, 2022 1.06 [0.77; 1.45] 0.98[0.76; 1.26]ACTIV-3/TICO LY-CoV555 , 2020, ITAC, 202220%899moderatenot evaluable hospital dischargedetailed resultsACTIV-3/TICO LY-CoV555 , 2020 0.97 [0.78; 1.20] 0.97[0.78; 1.20]ACTIV-3/TICO LY-CoV555 , 202010%314NAnot evaluable recoverydetailed resultsACTIV-3/TICO LY-CoV555 , 2020 1.06 [0.77; 1.46] 1.06[0.77; 1.46]ACTIV-3/TICO LY-CoV555 , 202010%314NAnot evaluable composite safety outcome detailed resultsACTIV-3/TICO LY-CoV555 , 2020 1.56 [0.78; 3.11] 1.56[0.78; 3.11]ACTIV-3/TICO LY-CoV555 , 202010%314NAnot evaluable serious adverse eventsdetailed resultsITAC, 2022 0.98 [0.66; 1.46] 0.98[0.66; 1.46]ITAC, 202210%579NAnot evaluable0.55.01.0relative treatment effectwww.metaEvidence.org2024-06-17 16:13 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 649,650,589,651,968 - roots T: 290